A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

Dermavant Sciences GmbH1 site in 1 country33 target enrollmentSeptember 27, 2019

ConditionsVitiligo

InterventionsCerdulatinib 0.37% gel Vehicle gel

DrugsCerdulatinib 0.37% gel Vehicle gel

Overview

Phase: Phase 2
Intervention: Cerdulatinib 0.37% gel
Conditions: Vitiligo
Sponsor: Dermavant Sciences GmbH
Enrollment: 33
Locations: 1
Primary Endpoint: Laboratory Values
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase 2a, randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, and systemic exposure of cerdulatinib gel, 0.37% in adults with vitiligo

Registry

clinicaltrials.gov

Start Date

September 27, 2019

End Date

November 3, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Dermavant Sciences GmbH

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male and female subjects age 18 and older with a confirmed clinical diagnosis of vitiligo for at least 3 months, including ≥0.5% to ≤30% BSA involvement.
•Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
•Capable of giving informed consent

Exclusion Criteria

•Diagnosis of segmental vitiligo
•Subjects with concurrent conditions or history of other diseases (e.g., current or chronic history of liver disease) that could affect the safety of the subject or the implementation of this study
•Use of any prohibited medication within the indicated period before the first dose of study drug
•Pregnant or lactating females
•Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 8 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's vitiligo
•The subject has received an investigational product within the following time period prior to the first dosing day: 4 weeks or 5 half-lives (whichever is longer).
•Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory test value abnormality that will affect the health of the subject or interfere with interpretation of the results
•History of sensitivity to the study drug, or components thereof or a history of drug or other allergy that contraindicates the subject's participation in the study;